Locations:
SearchAdvertisement
Phase 2 trial of zerlasiran yields first demonstration of longer effect with each dose of an siRNA
Metabolites from animal product substrates implicated in heart failure development in community cohorts
Resourceful approaches to the care of patients with microvascular disease and elevated Lp(a)
Study authors urge reevaluation of the sweetener’s safety designation by food regulators
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Studies reveal increased cardiac events, enhanced platelet reactivity and thrombotic potential
Reassurance from the lipid outcomes trial with the highest percentage female enrollment to date
Tech-assisted self-selection concurred with clinician-assessed eligibility in >90% of cases
Newly identified pathway may explain the so-called niacin paradox
It's time to increase testing for this major cardiovascular risk factor in advance of new therapies
Findings establish overweight/obesity as a modifiable risk factor for cardiovascular disease
Advertisement
Advertisement